XML 65 R27.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2015 and December 31, 2014:

		September 30, 2015
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent		$	31,951			$	(3,994	)		$	27,957				14
Development costs of
corporate website			91,743				(91,743	)			—				n/a
Approved hormone
therapy drug
candidate patents			605,502				(40,199	)			565,303				17.25
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)			585,241				—				585,241				n/a
Multiple trademarks for
vitamins/supplements			145,783				—				145,783				indefinite
Total		$	1,460,220			$	(135,936	)		$	1,324,284

		December 31, 2014
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent		$	31,951			$	(2,496	)		$	29,455				14.75
Development costs of
corporate website			91,743				(91,743	)			—				n/a
Approved hormone
therapy drug
candidate patents			439,184				(19,401	)			419,783				18
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents
(pending)			675,982				—				675,982				n/a
Multiple trademarks for
vitamins/supplements			103,368				—				103,368				indefinite
Total		$	1,342,228			$	(113,640	)		$	1,228,588

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,				Estimated Amortization
	2015 (3 months)			$	8,692
	2016			$	34,768
	2017			$	34,768
	2018			$	34,768
	2019			$	34,768